Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

EarningsInsider May. 13 at 12:46 PM

https://www.marketbeat.com/earnings/reports/2026-5-13-pds-biotechnology-co-stock/ $PDSB PDS Biotechnology Earnings Transcript

0 · Reply

StocktwitsEarnings May. 13 at 12:08 PM

$PDSB Q1 '26 Earnings Results & Recap Reported GAAP EPS of -$0.13 up 38.10% YoY

0 · Reply

Mr_Charlie May. 13 at 12:02 PM

$PDSB a lot of bla bla bla which means nothing. We will have to wait another year to ear anything meaninful. For the moment we hold hold hold.

1 · Reply

dvice2 May. 13 at 11:22 AM

$PDSB V-003 not even restarted yet 😂

1 · Reply

rwol9999 May. 13 at 11:06 AM

$PDSB Actual EPS: -$0.13 per share Consensus estimate: -$0.14 to -$0.15 Net loss: $7.3 million (improved from $8.5 million / -$0.21 in Q1 2025) Revenue: $0 (as expected for a pre-commercial biotech) Verdict: Beat — narrower-than-expected loss, continuing the trend of recent beats. Operating expenses were also lower (R&D down significantly).

0 · Reply

rwol9999 May. 13 at 11:04 AM

$PDSB beat by 2 cents

0 · Reply